Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

被引：8

作者：

Strutton, David R. ^{[1
]}

Farkouh, Raymond A. ^{[1
]}

Rubin, Jaime L. ^{[2
]}

McGarry, Lisa J. ^{[2
]}

Loiacono, Paul M. ^{[1
]}

Klugman, Keith P. ^{[3
]}

Pelton, Steven I. ^{[4
]}

Gilmore, Kristen E. ^{[2
]}

Weinstein, Milton C. ^{[5
]}

机构：

[1] Pfizer Inc, Vaccines Market Access & Outcomes Res Specialty C, Collegeville, PA 19426 USA

[2] Optuminsight, Medford, MA 02155 USA

[3] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA

[4] Boston Univ, Sch Med, Boston, MA 02118 USA

[5] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA

来源：

BMC INFECTIOUS DISEASES | 2012年 / 12卷

关键词：

Pneumococcal conjugate vaccine; Catch-up vaccination; Pneumococcal; PCV13; 13-valent; CHILDREN;

D O I：

10.1186/1471-2334-12-175

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%. Methods: This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant. Results: Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged <= 59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program. Conclusions: Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.

引用

页数：4

共 7 条

[1]

Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P258

[2]

California Department of Public Health State of California-Health and Human Services Agency, HLTH ADV FAT VACC PR

[3]

Centers for Disease Control and Prevention, EST VACC COV IND VAC

[4]

Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1

[5]

Harriman Kathleen, 2011, Morbidity and Mortality Weekly Report, V60, P1477

[6] Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts [J].

Nuorti, J. Pekka ;

Martin, Stacey W. ;

Smith, Philip J. ;

Moran, John S. ;

Schwartz, Benjamin .

AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2008, 34 (01) :46-53

[7] Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States [J].

Rubin, Jaime L. ;

McGarry, Lisa J. ;

Strutton, David R. ;

Klugman, Keith P. ;

Pelton, Stephen I. ;

Gilmore, Kristen E. ;

Weinstein, Milton C. .

VACCINE, 2010, 28 (48) :7634-7643

← 1 →